harmol has been researched along with Debility in 1 studies
Timeframe | Studies, this research(%) | All Research% |
---|---|---|
pre-1990 | 0 (0.00) | 18.7374 |
1990's | 0 (0.00) | 18.2507 |
2000's | 0 (0.00) | 29.6817 |
2010's | 0 (0.00) | 24.3611 |
2020's | 1 (100.00) | 2.80 |
Authors | Studies |
---|---|
Ballesteros-Gonzalez, Á; Costa-Machado, LF; Del Pino, I; Duerr, JS; Eisenberg, T; Fabregat-Safont, D; Fernandez-Marcos, PJ; Fornari, T; Galindo, MI; Garcia-Dominguez, E; Gomez, J; Gomez-Cabrera, MC; Herradon, G; Hofer, SJ; Houtkooper, RH; Lopez-Aceituno, JL; Loza, MI; Madeo, F; Magnes, C; McIntyre, RL; Megias, D; Perez, M; Plaza, A; Pozo, OJ; Sierra-Ramirez, A; Tapia-Gonzalez, A; Villanueva-Bermejo, D; Viña, J | 1 |
1 other study(ies) available for harmol and Debility
Article | Year |
---|---|
Peripheral modulation of antidepressant targets MAO-B and GABAAR by harmol induces mitohormesis and delays aging in preclinical models.
Topics: Adipose Tissue, Brown; Aging; AMP-Activated Protein Kinase Kinases; Animals; Antidepressive Agents; Caenorhabditis elegans; Drosophila melanogaster; Fatty Liver; Female; Frailty; Glucose Intolerance; Harmine; Insulin Resistance; Liver; Longevity; Male; Mice; Mitochondria; Mitophagy; Models, Animal; Monoamine Oxidase; Muscle Fibers, Skeletal; Muscle, Skeletal; Physical Conditioning, Animal; Prediabetic State; Receptors, GABA-A | 2023 |